fludarabine has been researched along with beta-Thalassemia in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Algeri, M; Alseraihy, A; Angelucci, E; Corbacioglu, S; Cseh, A; de la Fuente, J; Fisgin, T; Galimard, JE; Isgrò, A; Kleinschmidt, K; La La Nasa, G; Lankester, A; Locatelli, F; Lüftinger, R; Peters, C; Salzer, E; Smiers, FJ; Unal, E; Yesilipek, A; Zecca, M; Zubarovskaya, N | 1 |
| Abraham, A; Balasubramanian, P; Devasia, AJ; Fouzia, NA; George, B; Kavitha, ML; Korula, A; Kulkarni, UP; Lionel, S; Mathews, V; Pai, AA; Selvarajan, S; Sindhuvi, E; Srivastava, A | 1 |
| Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L | 1 |
| Antoniou, MN; Biswas, A; Buckley, SMK; Chan, JKY; Choolani, M; Dighe, NM; Johana, N; Mattar, CNZ; Sandikin, D; Shaw, SSW; Tan, KW; Tan, LG; Tan, YW; Waddington, SN | 1 |
| Chen, X; Huang, Y; Huang, Z; Lan, H; Ma, X; Meng, F; Sun, Q; Wu, B; Wu, S; Xu, J; Yao, Q; Zhu, Z | 1 |
| Chen, Y; Feng, J; Lin, F; Lu, N; Ma, Y; Shi, Y; Sun, L; Tang, L; Wang, N; Xing, C; Yu, K | 1 |
| Abdel-Rahman, F; Abu-Jazar, H; Al-Zaben, A; Frangoul, H; Ghatasheh, L; Hammada, T; Hussein, AA; Najjar, R; Natsheh, A; Sharma, S | 1 |
| Agarwal, R; Ball, JB; Hutchinson, SK; Kharbanda, S; Lamb, LS; McKenna, DH; Smith, AR; Wagner, JE; Weinberg, KI | 1 |
| Bernardo, ME; Caocci, G; Comoli, P; Cugno, C; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Merli, P; Piras, E; Vacca, A; Zecca, M | 1 |
| Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M | 1 |
| Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK | 1 |
| Amylon, M; Casella, JF; Chen, AR; Fuchs, EJ; Iannone, R; Jones, RJ; Storb, RF; Sullivan, KM; Walters, MC; Woolfrey, A | 1 |
| Chen, J; Li, JP; Zhang, T; Zhong, J; Zhu, KE | 1 |
| Abdul-Hai, A; Ackerstein, A; Aker, M; Amar, A; Bitan, M; Gesundheit, B; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Tsirigotis, P | 1 |
| Cantú, OE; Gómez-Almaguer, D; González-Llano, O; Hernández, NE; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ | 1 |
8 trial(s) available for fludarabine and beta-Thalassemia
| Article | Year |
|---|---|
Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an FBCA conditioning regimen.
Topics: Adult; Allografts; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine | 2018 |
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
Topics: Acute Disease; Adult; Allografts; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Infant; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Risk Factors; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2019 |
Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.
Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Infant; Male; Myeloablative Agonists; Retrospective Studies; Risk Factors; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; beta-Thalassemia; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Unrelated Donors; Vidarabine | 2014 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2008 |
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Bone Marrow Transplantation; Child; Child, Preschool; Female; Graft Survival; Hematopoiesis; Humans; Immunocompetence; Kinetics; Male; Pilot Projects; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases.
Topics: Adolescent; Adult; Ambulatory Care; beta-Thalassemia; Blood Component Transfusion; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Remission Induction; Survival Rate; Thrombocytopenia; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2000 |
7 other study(ies) available for fludarabine and beta-Thalassemia
| Article | Year |
|---|---|
Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Topics: Adolescent; Antineoplastic Agents; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Humans; Infant; Male; Retrospective Studies; Thiotepa; Vidarabine; Young Adult | 2022 |
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Retrospective Studies; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2021 |
A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model.
Topics: Animals; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Cell Survival; Cellular Microenvironment; Disease Models, Animal; Female; Fetal Therapies; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Hepatocytes; Lentivirus; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2018 |
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; beta-Thalassemia; Blood Group Incompatibility; Busulfan; Child, Preschool; Cyclosporine; Epstein-Barr Virus Infections; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Plasma Exchange; Red-Cell Aplasia, Pure; Remission, Spontaneous; Retrospective Studies; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Graft vs Host Disease; Humans; Male; Middle Aged; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |